ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

VCNX Vaccinex Inc

4.80
-0.04 (-0.83%)
Apr 18 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 11,273
Bid Price 4.25
Ask Price 4.70
News -
Day High 5.18

Low
4.432

52 Week Range

High
100.80

Day Low 4.432
Company Name Stock Ticker Symbol Market Type
Vaccinex Inc VCNX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.04 -0.83% 4.80 19:30:57
Open Price Low Price High Price Close Price Prev Close
4.71 4.432 5.18 4.80 4.84
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
212 11,273 $ 4.74 $ 53,380 - 4.432 - 100.80
Last Trade Time Type Quantity Stock Price Currency
19:30:56 40 $ 4.70 USD

Vaccinex Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
5.6M 1.17M - 570k -20.25M -17.36 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Vaccinex News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No VCNX Message Board. Create One! See More Posts on VCNX Message Board See More Message Board Posts

Historical VCNX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week6.787.204.4325.3514,552-1.98-29.20%
1 Month8.138.404.4326.5311,053-3.33-40.96%
3 Months7.949213.024.4329.9768,505-3.15-39.62%
6 Months12.618215.90964.43210.6581,668-7.82-61.96%
1 Year89.523100.804.43230.33281,445-84.72-94.64%
3 Years499.80688.804.432224.17330,380-495.00-99.04%
5 Years1,129.802,568.304.432694.74587,770-1,125.00-99.58%

Vaccinex Description

Vaccinex Inc is a clinical-stage biotechnology company. It is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The company's product pipeline includes pepinemab (VX15), which targets Huntington's Disease (HD) and non-small cell lung cancer (NSCLC) and also neurodegenerative disorders; VX5 Autoimmune for the treatment of MS and potentially for other autoimmune disorder; and others.

Your Recent History

Delayed Upgrade Clock